Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Breast imaging readers' performance in the PERFORMS test-set based assessment scheme within the MyPeBS international randomised study

  • Michalopoulou, Eleni
  • Darker, Iain
  • Iotti, Valentina
  • Slonim, Efrat
  • de Koning, Harry J.
  • Alcantara Souza, Rodrigo
  • Burrion, Jean-Benoit
  • Montgolfier, Sandrine de
  • Vissac-Sabatier, Cécile
  • Guindy, Michal
  • Pattacini, Pierpaolo
  • Delaloge, Suzette
  • Gilbert, Fiona J.
  • Chen, Yan
  • MyPeBS Consortium
Purpose: A survey conducted by the European Society of Breast Imaging (EUSOBI) in 2023 revealed significant variations in Quality Assurance (QA) practices across Europe. The UK encourages regular performance monitoring for screen readers. This study aimed to assess the variability in diagnostic performance among readers participating in a wider prospective randomised trial across multiple countries. Method: In this retrospective multinational study, breast imaging readers from the MyPeBS clinical trial examined a test set of 40 challenging breast screening cases using the PERFORMS software, from March 2021 to February 2022. The challenging set, enriched with biopsy-proven cancers, aimed to differentiate readers by their level of diagnostic performance. Cancer detection and correct return to screen rates were calculated for each participant. Results: A total of 110 readers from 6 countries completed the PERFORMS test set, while 88 also completed an accompanying questionnaire collecting information about their breast screening work and experience. The study revealed variability in cancer detection rates (M = 73.6 %, SD = 19.7 %, range 0.0 %-100.0 %) and correct return to screen rates (M = 79.7 %, SD = 10.5 %, range 46.4 %-100.0 %). Outliers with extremely low cancer detection (2.7 % of participants) and correct return to screen rates (1.8 % of participants) were also identified. Conclusions: Breast imaging readers' performance in test set-based assessments like PERFORMS can reflect real-world screening proficiency. The presence of outlier readers with low diagnostic performance on the test highlights the need for double reading and for standardised QA protocols to ensure patient safety and service efficiency., The current study is funded as part of the MyPeBS clinical trial, which is supported by the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 755394. The funders had no role in in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the manuscript for publication.
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Towards a European health research and innovation cloud (HRIC)

  • Aarestrup, Frank M.
  • Gut, Ivo Glynne
  • Sanz, Ferran
  • Van Oyen, Herman
The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrastructure. Creating a European Health Research and Innovation Cloud (HRIC) within this environment should enable data sharing and analysis for health research across the EU, in compliance with data protection legislation while preserving the full trust of the participants. Such a HRIC should learn from and build on existing data infrastructures, integrate best practices, and focus on the concrete needs of the community in terms of technologies, governance, management, regulation, and ethics requirements. Here, we describe the vision and expected benefits of digital data sharing in health research activities and present a roadmap that fosters the opportunities while answering the challenges of implementing a HRIC. For this, we put forward five specific recommendations and action points to ensure that a European HRIC: i) is built on established standards and guidelines, providing cloud technologies through an open and decentralized infrastructure; ii) is developed and certified to the highest standards of interoperability and data security that can be trusted by all stakeholders; iii) is supported by a robust ethical and legal framework that is compliant with the EU General Data Protection Regulation (GDPR); iv) establishes a proper environment for the training of new generations of data and medical scientists; and v) stimulates research and innovation in transnational collaborations through public and private initiatives and partnerships funded by the EU through Horizon 2020 and Horizon Europe., The workshop participants received funding from the European Union Seventh Program for Research, Technological Development and Demonstration (FP7) and Horizon Research and Innovation Program (H2020) and other European Union programs under the following grant agreements: AETIONOMY (Developing an Aetiology-based Taxonomy of Human Disease—Approaches to Develop a New Taxonomy for Neurological Disorders, IMI-no115568), ANTI-SUPERBUG PCP (ANTISUPERBUG Precommercial Procurement, H2020-no688878), B-CAST (Breast CAncer Stratification understanding the determinants of risk and prognosis of molecular sub-types, H2020-no633784), BRIDGE Health (Bridging information and data generation for evidence-based health policy and research, H2020-no664691), CASyM (Coordinating Action Systems Medicine—Implementation of Systems Medicine across Europe, FP7-n°305033), CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI, FP7-no602150), CECM (Centre for New Methods in Computational Diagnostics and Personalized Therapy, H2020-no763734), COLOSSUS (Advancing a Precision Medicine Paradigm in Metastatic Colorectal Cancer: Systems based patient stratification solutions, H2020-no754923), COMPARE (COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe, H2020-no643476), CONNECARE (Personalized Connected Care for Complex Chronic Patients, H2020-no689802), CREATIVE (Collaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in Europe, FP7-no602714), DEFORM (Define the global and financial impact of research misconduct H2020-no710246), ECCTR (European Cornea and Cell Transplant Registry, FP7-n°709723), E-COMPARED (European COMPARative Effectiveness Research on online Depression, FP7-no603098), ECRIN-IA (European Clinical Research Infrastructures Network- Integrating Activity, FP7-no284395), EHR4CR (Electronic Health Records Systems for Clinical Research, IMI-no115189) eInfraCentral (European E-infrastructures Services Gateway, H2020-no731049), ELIXIR (European Life-science Infrastructure for Biological Information, FP7-n°211601), ELIXIR-EXCELERATE (Fast track ELIXIR implementation and drive early user exploitation across the life sciences, H2020-no676559), eMEN (e-mental health innovation and transnational implementation platform North West Europe, H2020), EMIF (European Medical Information Framework, IMI-no115372), ERA PerMed (ERA-net Cofund in Personalized Medicine, H2020-no779282), eTRIKS (Delivering European Translational Information and Knowledge Management Services, IMI-1-no115446), EuroPOND (Data-driven models for progression of neurological diseases, H2020-n°666992), EurValve (Personalized Decision Support for Heart Valve disease, H2020-no689617), HBP SGA1/SGA2 (Human Brain Project specific grant agreements, H2020-n°720270/785907), ICT4DEPRESSION (User-friendly ICT tools to enhance self-management and effective treatment of depression in the EU, FP7-n°248778), ImpleMentAll (Towards evidence-based tailored implementation strategies for eHealth, H2020-no733025), INSTRUCT-ULTRA (Releasing the full potential of instruct to expand and consolidate infrastructure services for integrated structural life sciences research, H2020-no731005), MASTERMIND (Management of Mental Disorders through Advanced Technologies, CIP-no621000), MeDALL (Mechanisms of the Development of ALLergy, FP7-n°261357), MedBioinformatics (Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities, H2020-n°634143), MIDAS (Meaningful Integration of Data, Analytics and Services, H2020-no727721), MultipleMS (Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalized medicine, H2020-no733161), myPEBS (Randomized Comparison Of Risk-Stratified versus Standard Breast Cancer Screening European Women Aged 40–74, H2020-no755394), OpenAIRE-Advance (Advancing Open Scholarship, H2020-no777541), OpenMedicine (OpenMedicine, H2020-n°643796), PanCareSurFup (PanCare Childhood and Adolescent Cancer Survival Care and Follow-up Studies, FP7-n°257505), PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope, H2020-IMI-2-n°777492), PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics, FP7-n°602525), Regions4PerMed (Interregional coordination for a deep and fast uptake of personalized health, H2020-no825812), RD-CONNECT (An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, FP7-no305344), Solve-RD (Solving the unsolved Rare Diseases, H2020-no779257), SPIDIA4P (SPIDIA for Personalized Medicine-Standardization of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine, H2020-no733112), SYSCID (A Systems medicine approach to chronic inflammatory disease, H2020-no733100), SysCLAD (Systems prediction of Chronic Allograft Dysfunction, FP7-n°305457), SYSCOL (Systems Biology of Colorectal Cancer, FP7-no258236), SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease, H2020-n°668738), U-BIOPRED (Unbiased BIOmarkers for the PREDiction of respiratory disease outcomes, IMI-n°115010), VPH-share (Virtual Physiological Human: Sharing for Healthcare—A Research Environment, FP7-n°269978).
Repositorio Digital de la UPF
Publicación Artículo científico (JournalArticle)

Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial

  • Roux, Alexandra
  • Cholerton, Rachel
  • Sicsic, Jonathan
  • Moumjid, Nora
  • French, David P.
  • Rossi, Paolo G.
  • Balleyguier, Corinne
  • Guindy, Michal
  • Gilbert, Fiona J.
  • Burrion, Jean-Benoit
  • Castells, Xavier
  • Ritchie, David
  • Keatley, Debbie
  • Baron, Camille
  • Delaloge, Suzette
  • Montgolfier, Sandrine de
Background: the MyPeBS study is an ongoing randomised controlled trial testing whether a risk-stratified breast cancer screening strategy is non-inferior, or eventually superior, to standard age-based screening at reducing incidence of stage 2 or more cancers. This large European Commission-funded initiative aims to include 85,000 women aged 40 to 70 years, without prior breast cancer and not previously identified at high risk in six countries (Belgium, France, Italy, Israel, Spain, UK). A specific work package within MyPeBS examines psychological, socio-economic and ethical aspects of this new screening strategy. It compares women's reported data and outcomes in both trial arms on the following issues: general anxiety, cancer-related worry, understanding of breast cancer screening strategy and information-seeking behaviour, socio-demographic and economic characteristics, quality of life, risk perception, intention to change health-related behaviours, satisfaction with the trial. Methods: at inclusion, 3-months, 1-year and 4-years, each woman participating in MyPeBS is asked to fill online questionnaires. Descriptive statistics, bivariate analyses, subgroup comparisons and analysis of variations over time will be performed with appropriate tests to assess differences between arms. Multivariate regression models will allow modelling of different patient reported data and outcomes such as comprehension of the information provided, general anxiety or cancer worry, and information seeking behaviour. In addition, a qualitative study (48 semi-structured interviews conducted in France and in the UK with women randomised in the risk-stratified arm), will help further understand participants' acceptability and comprehension of the trial, and their experience of risk assessment. Discussion: beyond the scientific and medical objectives of this clinical study, it is critical to acknowledge the consequences of such a paradigm shift for women. Indeed, introducing a risk-based screening relying on individual biological differences also implies addressing non-biological differences (e.g. social status or health literacy) from an ethical perspective, to ensure equal access to healthcare. The results of the present study will facilitate making recommendations on implementation at the end of the trial to accompany any potential change in screening strategy., MyPeBS project is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement N°755394 and underwent a full external peer review process at this step. MyPeBS has received funding from the PHRC-K research-funding programme (17–154) for the conduct of the study in France. DPF is supported by the NIHR Biomedical Research Centre in Manchester (IS-BRC-1215–20007). FJG is supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215–20014). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. XC is supported by grants from Instituto de Salud Carlos III FEDER (PI19/00007). MyPeBS is supported by the French health insurance systems (CNAM, MSA, MGEN, CPRPSNCF) for the covering of screening exams extra-costs, and by the Malakoff Humanis social protection group through the financing of the equipment of the recruiting centres with digital tablets to inform women about the study.
Repositori Obert UdL
Publicación Artículo científico (JournalArticle)

"Unanswered questions": Acceptability of a personalised breast cancer screening strategy in lower-risk women by healthcare professionals in the context of the MyPeBS study

  • Laza-Vásquez, Celmira
  • Román, Marta
  • Delaloge, Suzette
  • De Montgolfier, Sandrine
  • Castells, Xavier
Background: Based on the relevant differences in breast cancer risk, strategies for personalizing population screening have been proposed. The present study was conducted in the context of the MyPEBS study, which seeks to improve the evidence on the benefits and risks of implementing personalized screening. We explored the views of healthcare professionals involved in the MyPeBS study on the acceptability to extend the screening interval in women at lower risk, as proposed by MyPeBS. Methods: Qualitative interpretative descriptive study. Twelve health professionals were interviewed individually and in a discussion group. The transcripts were analysed using thematic analysis. Results: For healthcare professionals, the low risk estimate was good news for women. However, the acceptability of decreasing screening frequency was not homogeneous. A lower uptake seemed to be mainly influenced by previous participation in current population-based screening. Several uncertainties were raised for acceptability: the benefits of such personalization for lower-risk women, how to guarantee equity, and the feasibility of this de-escalation in terms of human and financial resources. Conclusion: Previous participation in screening was the most significant factor for women's low acceptance of decreasing screening frequency. Future research should refine the views of health professionals and women. Recommendations should be made to promote participation in personalized screening of women at lower risk., The MyPeBS project is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement N° 755394. MyPeBS has received funding from project PI19/00007 of the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, for the conduct of the study in Spain. The funders played no role in the study design, data collection and analysis, manuscript drafting, or the decision to publish the results. The funding information (funders who received the grants). Instituto de Salud Carlos, III, PI19/00007, PhD Marta Román, PhD Xavier Castells, H2020 European Research Council, N° 755394, PhD Marta Román, PhD Suzette Delaloge, PhD Sandrine De Montgolfier.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Towards a European health research and innovation cloud (HRIC)

  • Aarestrup, Frank M.
  • Gut, Ivo Glynne
  • Sanz, Ferran
  • Van Oyen, Herman
The European Union (EU) initiative on the Digital Transformation of Health and Care (Digicare) aims to provide the conditions necessary for building a secure, flexible, and decentralized digital health infrastructure. Creating a European Health Research and Innovation Cloud (HRIC) within this environment should enable data sharing and analysis for health research across the EU, in compliance with data protection legislation while preserving the full trust of the participants. Such a HRIC should learn from and build on existing data infrastructures, integrate best practices, and focus on the concrete needs of the community in terms of technologies, governance, management, regulation, and ethics requirements. Here, we describe the vision and expected benefits of digital data sharing in health research activities and present a roadmap that fosters the opportunities while answering the challenges of implementing a HRIC. For this, we put forward five specific recommendations and action points to ensure that a European HRIC: i) is built on established standards and guidelines, providing cloud technologies through an open and decentralized infrastructure; ii) is developed and certified to the highest standards of interoperability and data security that can be trusted by all stakeholders; iii) is supported by a robust ethical and legal framework that is compliant with the EU General Data Protection Regulation (GDPR); iv) establishes a proper environment for the training of new generations of data and medical scientists; and v) stimulates research and innovation in transnational collaborations through public and private initiatives and partnerships funded by the EU through Horizon 2020 and Horizon Europe., The workshop participants received funding from the European Union Seventh Program for Research, Technological Development and Demonstration (FP7) and Horizon Research and Innovation Program (H2020) and other European Union programs under the following grant agreements: AETIONOMY (Developing an Aetiology-based Taxonomy of Human Disease—Approaches to Develop a New Taxonomy for Neurological Disorders, IMI-no115568), ANTI-SUPERBUG PCP (ANTISUPERBUG Precommercial Procurement, H2020-no688878), B-CAST (Breast CAncer Stratification understanding the determinants of risk and prognosis of molecular sub-types, H2020-no633784), BRIDGE Health (Bridging information and data generation for evidence-based health policy and research, H2020-no664691), CASyM (Coordinating Action Systems Medicine—Implementation of Systems Medicine across Europe, FP7-n°305033), CENTER-TBI (Collaborative European NeuroTrauma Effectiveness Research in TBI, FP7-no602150), CECM (Centre for New Methods in Computational Diagnostics and Personalized Therapy, H2020-no763734), COLOSSUS (Advancing a Precision Medicine Paradigm in Metastatic Colorectal Cancer: Systems based patient stratification solutions, H2020-no754923), COMPARE (COllaborative Management Platform for detection and Analyses of (Re-)emerging and foodborne outbreaks in Europe, H2020-no643476), CONNECARE (Personalized Connected Care for Complex Chronic Patients, H2020-no689802), CREATIVE (Collaborative REsearch on ACute Traumatic brain Injury in intensiVe care medicine in Europe, FP7-no602714), DEFORM (Define the global and financial impact of research misconduct H2020-no710246), ECCTR (European Cornea and Cell Transplant Registry, FP7-n°709723), E-COMPARED (European COMPARative Effectiveness Research on online Depression, FP7-no603098), ECRIN-IA (European Clinical Research Infrastructures Network- Integrating Activity, FP7-no284395), EHR4CR (Electronic Health Records Systems for Clinical Research, IMI-no115189) eInfraCentral (European E-infrastructures Services Gateway, H2020-no731049), ELIXIR (European Life-science Infrastructure for Biological Information, FP7-n°211601), ELIXIR-EXCELERATE (Fast track ELIXIR implementation and drive early user exploitation across the life sciences, H2020-no676559), eMEN (e-mental health innovation and transnational implementation platform North West Europe, H2020), EMIF (European Medical Information Framework, IMI-no115372), ERA PerMed (ERA-net Cofund in Personalized Medicine, H2020-no779282), eTRIKS (Delivering European Translational Information and Knowledge Management Services, IMI-1-no115446), EuroPOND (Data-driven models for progression of neurological diseases, H2020-n°666992), EurValve (Personalized Decision Support for Heart Valve disease, H2020-no689617), HBP SGA1/SGA2 (Human Brain Project specific grant agreements, H2020-n°720270/785907), ICT4DEPRESSION (User-friendly ICT tools to enhance self-management and effective treatment of depression in the EU, FP7-n°248778), ImpleMentAll (Towards evidence-based tailored implementation strategies for eHealth, H2020-no733025), INSTRUCT-ULTRA (Releasing the full potential of instruct to expand and consolidate infrastructure services for integrated structural life sciences research, H2020-no731005), MASTERMIND (Management of Mental Disorders through Advanced Technologies, CIP-no621000), MeDALL (Mechanisms of the Development of ALLergy, FP7-n°261357), MedBioinformatics (Creating medically-driven integrative bioinformatics applications focused on oncology, CNS disorders and their comorbidities, H2020-n°634143), MIDAS (Meaningful Integration of Data, Analytics and Services, H2020-no727721), MultipleMS (Multiple manifestations of genetic and non-genetic factors in Multiple Sclerosis disentangled with a multi-omics approach to accelerate personalized medicine, H2020-no733161), myPEBS (Randomized Comparison Of Risk-Stratified versus Standard Breast Cancer Screening European Women Aged 40–74, H2020-no755394), OpenAIRE-Advance (Advancing Open Scholarship, H2020-no777541), OpenMedicine (OpenMedicine, H2020-n°643796), PanCareSurFup (PanCare Childhood and Adolescent Cancer Survival Care and Follow-up Studies, FP7-n°257505), PIONEER (Prostate Cancer DIagnOsis and TreatmeNt Enhancement through the Power of Big Data in EuRope, H2020-IMI-2-n°777492), PREPARE (Platform for European Preparedness Against (Re-)emerging Epidemics, FP7-n°602525), Regions4PerMed (Interregional coordination for a deep and fast uptake of personalized health, H2020-no825812), RD-CONNECT (An integrated platform connecting registries, biobanks and clinical bioinformatics for rare disease research, FP7-no305344), Solve-RD (Solving the unsolved Rare Diseases, H2020-no779257), SPIDIA4P (SPIDIA for Personalized Medicine-Standardization of generic Pre-analytical procedures for In-vitro DIAgnostics for Personalized Medicine, H2020-no733112), SYSCID (A Systems medicine approach to chronic inflammatory disease, H2020-no733100), SysCLAD (Systems prediction of Chronic Allograft Dysfunction, FP7-n°305457), SYSCOL (Systems Biology of Colorectal Cancer, FP7-no258236), SysMedPD (Systems Medicine of Mitochondrial Parkinson’s Disease, H2020-n°668738), U-BIOPRED (Unbiased BIOmarkers for the PREDiction of respiratory disease outcomes, IMI-n°115010), VPH-share (Virtual Physiological Human: Sharing for Healthcare—A Research Environment, FP7-n°269978).
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Breast imaging readers' performance in the PERFORMS test-set based assessment scheme within the MyPeBS international randomised study

  • Michalopoulou, Eleni
  • Darker, Iain
  • Iotti, Valentina
  • Slonim, Efrat
  • de Koning, Harry J.
  • Alcantara Souza, Rodrigo
  • Burrion, Jean-Benoit
  • de Montgolfier, Sandrine
  • Vissac-Sabatier, Cécile
  • Guindy, Michal
  • Pattacini, Pierpaolo
  • Delaloge, Suzette
  • Gilbert, Fiona J.
  • Chen, Yan
  • MyPeBS Consortium
Purpose: A survey conducted by the European Society of Breast Imaging (EUSOBI) in 2023 revealed significant variations in Quality Assurance (QA) practices across Europe. The UK encourages regular performance monitoring for screen readers. This study aimed to assess the variability in diagnostic performance among readers participating in a wider prospective randomised trial across multiple countries. Method: In this retrospective multinational study, breast imaging readers from the MyPeBS clinical trial examined a test set of 40 challenging breast screening cases using the PERFORMS software, from March 2021 to February 2022. The challenging set, enriched with biopsy-proven cancers, aimed to differentiate readers by their level of diagnostic performance. Cancer detection and correct return to screen rates were calculated for each participant. Results: A total of 110 readers from 6 countries completed the PERFORMS test set, while 88 also completed an accompanying questionnaire collecting information about their breast screening work and experience. The study revealed variability in cancer detection rates (M = 73.6 %, SD = 19.7 %, range 0.0 %-100.0 %) and correct return to screen rates (M = 79.7 %, SD = 10.5 %, range 46.4 %-100.0 %). Outliers with extremely low cancer detection (2.7 % of participants) and correct return to screen rates (1.8 % of participants) were also identified. Conclusions: Breast imaging readers' performance in test set-based assessments like PERFORMS can reflect real-world screening proficiency. The presence of outlier readers with low diagnostic performance on the test highlights the need for double reading and for standardised QA protocols to ensure patient safety and service efficiency., The current study is funded as part of the MyPeBS clinical trial, which is supported by the European Union's Horizon 2020 Research and Innovation Programme under grant agreement No. 755394. The funders had no role in in study design; in the collection, analysis and interpretation of data; in the writing of the report; and in the decision to submit the manuscript for publication.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

Study protocol comparing the ethical, psychological and socio-economic impact of personalised breast cancer screening to that of standard screening in the "My Personal Breast Screening" (MyPeBS) randomised clinical trial

  • Roux, Alexandra
  • Cholerton, Rachel
  • Sicsic, Jonathan
  • Moumjid, Nora
  • French, David P.
  • Rossi, Paolo G.
  • Balleyguier, Corinne
  • Guindy, Michal
  • Gilbert, Fiona J.
  • Burrion, Jean-Benoit
  • Castells, Xavier
  • Ritchie, David
  • Keatley, Debbie
  • Baron, Camille
  • Delaloge, Suzette
  • Montgolfier, Sandrine de
Background: the MyPeBS study is an ongoing randomised controlled trial testing whether a risk-stratified breast cancer screening strategy is non-inferior, or eventually superior, to standard age-based screening at reducing incidence of stage 2 or more cancers. This large European Commission-funded initiative aims to include 85,000 women aged 40 to 70 years, without prior breast cancer and not previously identified at high risk in six countries (Belgium, France, Italy, Israel, Spain, UK). A specific work package within MyPeBS examines psychological, socio-economic and ethical aspects of this new screening strategy. It compares women's reported data and outcomes in both trial arms on the following issues: general anxiety, cancer-related worry, understanding of breast cancer screening strategy and information-seeking behaviour, socio-demographic and economic characteristics, quality of life, risk perception, intention to change health-related behaviours, satisfaction with the trial. Methods: at inclusion, 3-months, 1-year and 4-years, each woman participating in MyPeBS is asked to fill online questionnaires. Descriptive statistics, bivariate analyses, subgroup comparisons and analysis of variations over time will be performed with appropriate tests to assess differences between arms. Multivariate regression models will allow modelling of different patient reported data and outcomes such as comprehension of the information provided, general anxiety or cancer worry, and information seeking behaviour. In addition, a qualitative study (48 semi-structured interviews conducted in France and in the UK with women randomised in the risk-stratified arm), will help further understand participants' acceptability and comprehension of the trial, and their experience of risk assessment. Discussion: beyond the scientific and medical objectives of this clinical study, it is critical to acknowledge the consequences of such a paradigm shift for women. Indeed, introducing a risk-based screening relying on individual biological differences also implies addressing non-biological differences (e.g. social status or health literacy) from an ethical perspective, to ensure equal access to healthcare. The results of the present study will facilitate making recommendations on implementation at the end of the trial to accompany any potential change in screening strategy., MyPeBS project is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement N°755394 and underwent a full external peer review process at this step. MyPeBS has received funding from the PHRC-K research-funding programme (17–154) for the conduct of the study in France. DPF is supported by the NIHR Biomedical Research Centre in Manchester (IS-BRC-1215–20007). FJG is supported by the NIHR Cambridge Biomedical Research Centre (BRC-1215–20014). The views expressed are those of the authors and not necessarily those of the NHS, the NIHR, or the Department of Health and Social Care. XC is supported by grants from Instituto de Salud Carlos III FEDER (PI19/00007). MyPeBS is supported by the French health insurance systems (CNAM, MSA, MGEN, CPRPSNCF) for the covering of screening exams extra-costs, and by the Malakoff Humanis social protection group through the financing of the equipment of the recruiting centres with digital tablets to inform women about the study.
Recercat. Dipósit de la Recerca de Catalunya
Publicación Artículo científico (JournalArticle)

"Unanswered questions": Acceptability of a personalised breast cancer screening strategy in lower-risk women by healthcare professionals in the context of the MyPeBS study

  • Laza-Vásquez, Celmira
  • Román, Marta
  • Delaloge, Suzette
  • De Montgolfier, Sandrine
  • Castells, Xavier
Background: Based on the relevant differences in breast cancer risk, strategies for personalizing population screening have been proposed. The present study was conducted in the context of the MyPEBS study, which seeks to improve the evidence on the benefits and risks of implementing personalized screening. We explored the views of healthcare professionals involved in the MyPeBS study on the acceptability to extend the screening interval in women at lower risk, as proposed by MyPeBS. Methods: Qualitative interpretative descriptive study. Twelve health professionals were interviewed individually and in a discussion group. The transcripts were analysed using thematic analysis. Results: For healthcare professionals, the low risk estimate was good news for women. However, the acceptability of decreasing screening frequency was not homogeneous. A lower uptake seemed to be mainly influenced by previous participation in current population-based screening. Several uncertainties were raised for acceptability: the benefits of such personalization for lower-risk women, how to guarantee equity, and the feasibility of this de-escalation in terms of human and financial resources. Conclusion: Previous participation in screening was the most significant factor for women's low acceptance of decreasing screening frequency. Future research should refine the views of health professionals and women. Recommendations should be made to promote participation in personalized screening of women at lower risk., The MyPeBS project is funded by the European Union’s Horizon 2020 research and innovation programme under grant agreement N° 755394. MyPeBS has received funding from project PI19/00007 of the Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union, for the conduct of the study in Spain. The funders played no role in the study design, data collection and analysis, manuscript drafting, or the decision to publish the results. The funding information (funders who received the grants). Instituto de Salud Carlos, III, PI19/00007, PhD Marta Román, PhD Xavier Castells, H2020 European Research Council, N° 755394, PhD Marta Román, PhD Suzette Delaloge, PhD Sandrine De Montgolfier.